USV eyes Rs 2,000 crore revenue by 2015

Mumbai-based pharmaceutical company USV Limited, leader in anti-diabetic drug segment, is eyeing Rs 2,000-crore revenue by 2015. Currently, of the total revenue generated by USV Limited domestic operations (Rs 1,190 crore), 69 per cent is generated through domestic operations while international operations contribute 31 per cent (Rs 365 crore).

USV which enjoys market share of 14 per cent claims to be the leader of oral anti-diabetic segment, both in terms of value and prescription. USV Limited Managing Director Prashant Tewari maintained, the company expects by 2015 the domestic revenue would increase to Rs 1,400 crore while overseas market would contribute Rs 600 crore revenue.

 

Tewari was here to launch USV manufacturing at Baddi (Himachal Pradesh). Spread over three acres and built at a cost of over Rs 80 crore, the facility at Baddi is the second USV manufacturing site for solid orals for anti-diabetic and cardiovascular therapeutic segments. The plant has manufacturing capability for 220 billion tablets and 1,200 tonnage of granules in a year. The new Baddi facility will boost the Company’s manufacturing capability to address the growing market needs, both in India and internationally.